- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ , Pharmaceutical Technology - Pharma News and Development Insights. All rights reserved.
Featured Content
European Biotech Targeting Anti-ageing
Oct 2nd 2024
Novel mitophagy inducers and gene therapies that restore cellular function and decelerate the ageing process.
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?
Mar 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Training for Operational Excellence
Dec 3rd 2023
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
Billions of Reasons to be Buoyant
Sep 2nd 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
Latest Videos
Latest News
Behind the Headlines Episode 26: Clinical Advances, Weight-Loss Deals, and Swiss Startup Strength
October 1st 2025
Pfizer re-balances weight loss portfolio with Metsera, Bristol Myers Squibb and Roche make breast cancer progress, and Keytruda gets under your skin.
Behind the Headlines Episode 25: Major Big Pharma Moves, Pressures of Capital Markets at Intersection with Autologous Versus Allogeneic
September 24th 2025
Alvin Jogasuria, ProBio; Matthew Lunning, University of Nebraska Medical Center; and Carl Schoellhammer, DeciBio, go behind the headlines to discuss the need for doing more with less.
Pfizer’s $4.9 Billion Acquisition of Metsera Enhances Obesity Drug Pipeline
September 23rd 2025
Pfizer gains access to Metsera’s oral and injectable obesity candidates, underscoring innovation in drug development and scalable manufacturing.
Behind the Headlines Episode 24: Surging Implementation of Sequence Event Reporting in CMC Analytics, Billion Dollar Deals Push Further Consolidation or Collapse, and an Analytics Wish List
September 9th 2025
Aaron Cowley, Recipharm Advanced Bio; Renee Hart, LumaCyte; and Vibha Jawa, EpiVax, go behind the headlines to delve deeper into recent market deals driven by Big Pharma patent cliffs and the complex manufacturing of ATMPs.
Survey: Impacts of Tariffs and Trade Policy on the Bio/pharmaceutical Industry
August 1st 2025
Help us get a better picture of how new tariffs and trade policy have impacted you and your organization.
Behind the Headlines, Episode 18: Sanofi, GSK Go Big in M&A, mRNA Momentum Falters, and More
June 4th 2025
Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.
Behind the Headlines, Episode 17: Bespoke CRISPR Therapy, Executive Order Fallout, and More
May 21st 2025
Jamie Baumgartner, Jonathan Grinstein, and John Wilkerson go behind the headlines to discuss the implications of personalized gene-editing therapies, more HHS policy and funding updates, and the latest tariff-related investments.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025
On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Pharma 4.0: What are Industry Leaders Prioritizing in the Modernization of Pharmaceutical Manufacturing?
April 3rd 2025
The move towards “pharma 4.0” requires a major shift, both ideologically and technologically, to adapt current processes to a framework that will automate much of today’s manufacturing.
Industry Outlook 2025: Continuing Innovation
March 20th 2025
In an interview with Pharmaceutical Technology®, Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.